Bo Dai
Impact in
- Cancer Research top 2%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
- Oncology top 2%
- Cancer Immunotherapy and Biomarkers
Papers in
-
- Prostate Cancer Treatment and Research 42
- Renal cell carcinoma treatment 32
- Prostate Cancer Diagnosis and Treatment 24
-
- Renal and related cancers 16
- Co-authors
- Yao Zhu (76 shared papers)Yijun Shen (43 shared papers)Dingwei Ye (39 shared papers)Guohai Shi (32 shared papers)Yiping Zhu (24 shared papers)Yu Zhu (23 shared papers)Dingwei Ye (16 shared papers)Jiejie Xu (21 shared papers)
- Journals
- Asian Journal of Andrology (16 papers)Scientific Reports (10 papers)Journal of Cancer (9 papers)Oncotarget (8 papers)OncoImmunology (6 papers)
- Partner nations
- ChinaUnited StatesSingapore
In The Last Decade
Bo Dai
143 papers receiving 3.3k citations
Bo Dai's Hit Papers
Peers
Comparison fields: 5 of 114
- Cancer Research 1.0k
- Oncology 1.1k
- Pulmonary and Respiratory Medicine 1.3k
- Immunology 580
- Molecular Biology 1.4k
Countries citing papers authored by Bo Dai
This map shows the geographic impact of Bo Dai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bo Dai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bo Dai more than expected).
Fields of papers citing papers by Bo Dai
This network shows the impact of papers produced by Bo Dai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bo Dai. The network helps show where Bo Dai may publish in the future.
Co-authors
The 25 scholars most cited alongside Bo Dai, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 144 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2010 | 262 | |
| 2 | 2018 | 164 | |
| 3 | 2018 | 127 | |
| 4 | 2015 | 125 | |
| 5 | 2019 | 102 | |
| 6 | 2015 | 102 | |
| 7 | 2016 | 86 | |
| 8 | Tumor immunotherapy resistance: Revealing the mechanism of PD-1 / PD-L1-mediated tumor immune escape Hit paper breakdown → | 2024 | 80 |
| 9 | 2020 | 67 | |
| 10 | 2018 | 64 | |
| 11 | 2013 | 60 | |
| 12 | 2013 | 56 | |
| 13 | 2012 | 51 | |
| 14 | 2012 | 51 | |
| 15 | 2014 | 46 | |
| 16 | 2015 | 44 | |
| 17 | 2019 | 43 | |
| 18 | 2009 | 42 | |
| 19 | 2010 | 42 | |
| 20 | 2020 | 40 |
About Bo Dai
Bo Dai is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology, Oncology, Surgery and Cancer Research, having authored 144 papers that have together received 3.3k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (42 papers), Renal cell carcinoma treatment (32 papers), Bladder and Urothelial Cancer Treatments (31 papers), Prostate Cancer Diagnosis and Treatment (24 papers), Cancer Immunotherapy and Biomarkers (21 papers), Renal and related cancers (16 papers), Cancer, Lipids, and Metabolism (13 papers) and Urinary and Genital Oncology Studies (11 papers). The work is most often cited by research in Cancer Research (1.0k citations), Oncology (1.1k citations), Pulmonary and Respiratory Medicine (1.3k citations), Immunology (580 citations) and Molecular Biology (1.4k citations). Bo Dai has collaborated with scholars based in China, United States and Singapore. Frequent co-authors include Yao Zhu, Yijun Shen, Dingwei Ye, Guohai Shi, Yiping Zhu, Yu Zhu, Dingwei Ye, Jiejie Xu, Fangning Wan and Junyu Zhang. Their work appears in journals such as Asian Journal of Andrology, Scientific Reports, Journal of Cancer, Oncotarget and OncoImmunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.